Integrating Portal Hypertension Into HCC Management: Nature Reviews Gastroenterology & Hepatology | August 2026

Introduction:

Cirrhosis, portal hypertension, and hepatocellular carcinoma (HCC) are closely interconnected, yet clinical guidelines frequently approach portal hypertension and HCC as separate entities. This review proposes an integrated, stage-based framework combining the severity of underlying cirrhosis, clinically significant portal hypertension (CSPH), and HCC stage to improve prognostication and treatment selection.

Why was this study needed?

. Portal hypertension substantially influences both cirrhosis outcomes and eligibility for HCC therapies.

. Current HCC algorithms inadequately integrate the prognostic stage of underlying cirrhosis.

. CSPH is a major determinant of decompensation and can limit potentially curative treatments such as hepatic resection.

. Noninvasive assessment could simplify CSPH evaluation and improve individualized HCC management.

Results:

The proposed framework stratifies cirrhosis into compensated, decompensated, and further decompensated stages, while incorporating HCC stages from very early through advanced disease. Within compensated cirrhosis, the presence or absence of CSPH becomes a key prognostic and therapeutic discriminator. Although CSPH is conventionally defined by a hepatic venous pressure gradient ≥10 mmHg, liver stiffness measurement combined with platelet count has largely replaced invasive measurement in routine cirrhosis care. Emerging evidence suggests that these noninvasive approaches could also become applicable in patients with HCC. Integrating CSPH with both cirrhosis and tumor stage provides a more clinically meaningful assessment of hepatic reserve, decompensation risk, treatment feasibility, and prognosis.

Clinical Impact:

HCC treatment decisions should consider not only tumor burden but also the biological stage of the underlying liver disease. Incorporating CSPH may refine selection for resection, transplantation, locoregional therapy, and systemic treatment while better predicting the risk of hepatic decompensation. Future HCC trials should similarly stratify patients according to cirrhosis stage.

Bottom Line:

HCC management should integrate tumor stage with cirrhosis severity and CSPH, creating a unified framework that better reflects prognosis, hepatic reserve, and suitability for cancer-directed therapy.